Analyst firms · Morgan Stanley · BMY

Morgan Stanley BMY price target and rating history

Bristol-Myers Squibb Company (BMY) · Health Care

Morgan Stanley rates Bristol-Myers Squibb Company (BMY) Underweight with a $64 price target, as of its latest action on Apr 6, 2022. It has published 3 rating actions on BMY since July 2021, including 0 upgrades and 0 downgrades. Across 7 firms with a BMY price target in the last 12 months, the median target is $62.

Current rating
Underweight
Price target
$64
Median target, all firms
$62
Actions on BMY
3

Morgan Stanley price target on BMY

$71$68$6420222023202420252026
Morgan Stanley price target on BMY, each point a stated target, July 2021 to April 2022.

Every Morgan Stanley rating on BMY

How other firms rate BMY

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Leerink PartnersMarket Perform$59Oct 5, 2026
Argus ResearchBuy$75Aug 5, 2026
RBC Capital MarketsSector Perform$60Feb 25, 2026
BarclaysOverweight$75Feb 20, 2026
UBSBuy$65Jan 7, 2026
BofA SecuritiesBuy$61Dec 15, 2025
GuggenheimBuy$62Dec 12, 2025

Questions about Morgan Stanley and BMY

What is Morgan Stanley's price target for BMY?
Morgan Stanley's latest stated price target for Bristol-Myers Squibb Company (BMY) is $64, from its action on Apr 6, 2022.
What is Morgan Stanley's rating on BMY?
Morgan Stanley rates BMY Underweight, a bearish rating, as of Apr 6, 2022.
When did Morgan Stanley last change its view on BMY?
On Apr 6, 2022, Morgan Stanley resumes coverage at Underweight, price target $64.
How does Morgan Stanley's BMY target compare with other analysts?
Across 7 firms with a BMY price target in the last 12 months, the median target is $62.

More BMY rating histories

All Morgan Stanley ratingsBMY news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.